OncoMatch/Clinical Trials/NCT06926790
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Is NCT06926790 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nivolumab & Ipilimumab for lung cancer - non small cell.
Treatment: Nivolumab & Ipilimumab — Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression \<1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Biomarker criteria
Required: EGFR wild-type
without EGFR, ALK mutation
Required: ALK wild-type
without EGFR, ALK mutation
Required: PD-L1 (CD274) no known expression or ≤ 1% (no known expression or ≤ 1%)
no known PD-L1 expression or PD-L1 ≤ 1%
Disease stage
Required: Stage II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy
Cannot have received: radiotherapy
Lab requirements
Kidney function
No major organ dysfunction, including liver, kidney, and cardiac function
Liver function
No major organ dysfunction, including liver, kidney, and cardiac function
Cardiac function
No major organ dysfunction, including liver, kidney, and cardiac function
No major organ dysfunction, including liver, kidney, and cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06926790 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 no known expression or ≤ 1% is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify